Agios Pharmaceuticals, Inc. (AGIO)
NASDAQ: AGIO · Real-Time Price · USD
27.48
-0.68 (-2.41%)
At close: May 4, 2026, 4:00 PM EDT
27.56
+0.08 (0.29%)
After-hours: May 4, 2026, 4:10 PM EDT
Agios Pharmaceuticals Employees
As of December 31, 2025, Agios Pharmaceuticals had 540 total employees, including 539 full-time and 1 part-time employees. The number of employees increased by 52 or 10.66% compared to the previous year.
Employees
540
Change (1Y)
52
Growth (1Y)
10.66%
Revenue / Employee
$122,311
Profits / Employee
-$782,598
Market Cap
1.63B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 540 | 52 | 10.66% | 539 | 1 |
| Dec 31, 2024 | 488 | 102 | 26.42% | 486 | 2 |
| Dec 31, 2023 | 386 | -7 | -1.78% | 383 | 3 |
| Dec 31, 2022 | 393 | 1 | 0.26% | 389 | 4 |
| Dec 31, 2021 | 392 | -170 | -30.25% | 390 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Iovance Biotherapeutics | 975 |
| Intellia Therapeutics | 377 |
| Vir Biotechnology | 367 |
| Nurix Therapeutics | 317 |
| Nuvation Bio | 298 |
| Innoviva | 159 |
| Monte Rosa Therapeutics | 150 |
| AtaiBeckley | 99 |
AGIO News
- 5 days ago - Agios Pharmaceuticals Earnings Call Transcript: Q1 2026 - Transcripts
- 5 days ago - Agios Reports First Quarter 2026 Financial Results and Provides Business Update - GlobeNewsWire
- 4 weeks ago - Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - GlobeNewsWire
- 4 weeks ago - PK Activation Gains Momentum in Thalassemia Agios' Aqvesme Launch Reflects Strong Promise with Deliberate Uptake - GlobeNewsWire
- 4 weeks ago - Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Agios' PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in the United Arab Emirates - GlobeNewsWire
- 2 months ago - Agios Pharmaceuticals Earnings Call Transcript: Q4 2025 - Transcripts